Literature DB >> 20693417

Using open source computational tools for predicting human metabolic stability and additional absorption, distribution, metabolism, excretion, and toxicity properties.

Rishi R Gupta1, Eric M Gifford, Ted Liston, Chris L Waller, Moses Hohman, Barry A Bunin, Sean Ekins.   

Abstract

Ligand-based computational models could be more readily shared between researchers and organizations if they were generated with open source molecular descriptors [e.g., chemistry development kit (CDK)] and modeling algorithms, because this would negate the requirement for proprietary commercial software. We initially evaluated open source descriptors and model building algorithms using a training set of approximately 50,000 molecules and a test set of approximately 25,000 molecules with human liver microsomal metabolic stability data. A C5.0 decision tree model demonstrated that CDK descriptors together with a set of Smiles Arbitrary Target Specification (SMARTS) keys had good statistics [κ = 0.43, sensitivity = 0.57, specificity = 0.91, and positive predicted value (PPV) = 0.64], equivalent to those of models built with commercial Molecular Operating Environment 2D (MOE2D) and the same set of SMARTS keys (κ = 0.43, sensitivity = 0.58, specificity = 0.91, and PPV = 0.63). Extending the dataset to ∼193,000 molecules and generating a continuous model using Cubist with a combination of CDK and SMARTS keys or MOE2D and SMARTS keys confirmed this observation. When the continuous predictions and actual values were binned to get a categorical score we observed a similar κ statistic (0.42). The same combination of descriptor set and modeling method was applied to passive permeability and P-glycoprotein efflux data with similar model testing statistics. In summary, open source tools demonstrated predictive results comparable to those of commercial software with attendant cost savings. We discuss the advantages and disadvantages of open source descriptors and the opportunity for their use as a tool for organizations to share data precompetitively, avoiding repetition and assisting drug discovery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20693417     DOI: 10.1124/dmd.110.034918

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  27 in total

1.  DemQSAR: predicting human volume of distribution and clearance of drugs.

Authors:  Ozgur Demir-Kavuk; Jörg Bentzien; Ingo Muegge; Ernst-Walter Knapp
Journal:  J Comput Aided Mol Des       Date:  2011-11-20       Impact factor: 3.686

2.  Chemical space: missing pieces in cheminformatics.

Authors:  Sean Ekins; Rishi R Gupta; Eric Gifford; Barry A Bunin; Chris L Waller
Journal:  Pharm Res       Date:  2010-08-04       Impact factor: 4.200

3.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

4.  Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors.

Authors:  Yan-Yan Zhang; Yong Liu; Shahila Mehboob; Jin-Hua Song; Teuta Boci; Michael E Johnson; Arun K Ghosh; Hyunyoung Jeong
Journal:  Xenobiotica       Date:  2013-10-30       Impact factor: 1.908

5.  Making Transporter Models for Drug-Drug Interaction Prediction Mobile.

Authors:  Sean Ekins; Alex M Clark; Stephen H Wright
Journal:  Drug Metab Dispos       Date:  2015-07-21       Impact factor: 3.922

6.  A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery.

Authors:  Ignacio Aliagas; Alberto Gobbi; Timothy Heffron; Man-Ling Lee; Daniel F Ortwine; Mark Zak; S Cyrus Khojasteh
Journal:  J Comput Aided Mol Des       Date:  2015-02-24       Impact factor: 3.686

7.  Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis.

Authors:  Sean Ekins; Allen C Casey; David Roberts; Tanya Parish; Barry A Bunin
Journal:  Tuberculosis (Edinb)       Date:  2013-12-19       Impact factor: 3.131

Review 8.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.

Authors:  Sean Ekins; Joel S Freundlich; Inhee Choi; Malabika Sarker; Carolyn Talcott
Journal:  Trends Microbiol       Date:  2010-12-02       Impact factor: 17.079

Review 9.  Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Authors:  Sean Ekins; Anna Coulon Spektor; Alex M Clark; Krishna Dole; Barry A Bunin
Journal:  Drug Discov Today       Date:  2016-11-22       Impact factor: 7.851

10.  Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis.

Authors:  Sean Ekins; Joel S Freundlich; Robert C Reynolds
Journal:  J Chem Inf Model       Date:  2014-07-17       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.